Royalty Report: Drugs, Cancer, Biotechnology – Collection: 27681

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27681

License Grant
Licensor hereby grants to Company and Company hereby accepts from Licensor, an exclusive, worldwide right and license to use Materials solely in the Field, with the right to sublicense, to develop, have developed, register, use, make, have made, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, and import Licensed Products Licensor also-grant to Company the exclusive right to utilize the Licensed Know-How solely to make Licensed Products and to sell Licensed Products in the Field. Further, Company's Affiliates that are sublicensed under the foregoing licenses shall have the right to further sublicense such rights pursuant to the terms of this Agreement.
License Property
Licensor in accordance herewith, is in possession of BC8 monoclonal antibody and related master cell bank.

Licensed Products means any product or process which utilizes master cell bank (MCB) or the BC8 monoclonal antibody (MAb).

Licensed Know-How means the MCB, MCB documentation, BC8 MAb manufacturing documentation and all clinical, preclinical and technical data owned or controlled by Licensor related to the BC8 program.

Materials means BC8 MAb and all relevant Investigational New Drug (IND) and Drug Master Files.

The Licensee will build upon previous and ongoing clinical trials, with BC8 (licensed antibody) and eventually develop a clinical trial with Actinium 225.  

The Licensor has currently completed Phase I and Phase II of the clinical trial and the Licensee intends to start preparation for a pivotal trial leading to an FDA approval.

Actinium is a radioactive chemical element. Its current applications include a neutron source and an agent for radiation therapy targeting cancer cells in the body.

Field of Use
Licensed Field means the treatment, diagnosis, prevention and monitoring of diseases and other medical conditions in humans and animals.

IPSCIO Record ID: 1010

License Grant
Licensor hereby grants, and Licensee herby accepts, an exclusive, worldwide license, including the right to grant sublicenses, under the Licensor's Patent Rights and Licenso's Technical Information, to research, develop, make, have made, import, market, promote, use, sell, offer to sell and have sold Licensed Products in the Field.  Licensee shall have the right to grant sublicenses of its rights.
License Property
Licensor owns certain patents and related patent applications related to humanized antibodies and antibody humanization technology.
Licensor has certain rights to a humanized antibody directed against the CD33 antigen and designated by Licensor as HuM195.

HuM195 Antibody means the humanized version of the m195 antibody directed against the CD33 antigen.

Patent No. 5,585,089, Humanized Immunoglobulins
Patent No. 5,693,761, Polynucleotides Encoding Improved Humanized Immunoglobulins
Patent No. 5,693,762, Humanized Immunoglobulins
Patent No. 6,180, 370 Humanized Immunoglobulins and Method of Making the Same

Field of Use
Field means any form or derivative of the HuM195 Antibody conjugated with Actinium -225 or other alpha emitting radioisotopes (the HuM195 Antibody conjugate), including without limitation conjugates with biospecific, less than full-length antibody forms such as Fv, Fab, and F(ab), single-chain antibodies and hybrid antibodies, provided however, that the Field shall not include the unconjugated HuM195 Antibody (except as delivered as part of a mixture with the HuM195 Antibody Conjugate and delivered as a single therapy), the HuM195 Antibody conjugated with any radionuclide other than Actinium-225 or other alpha emitters, or the HuM105 Antibody conjugated with a peptide or small molecule toxin.

The Licensee secured exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes.

Alpha particles are of considerable interest for radioimmunotherapy applications since their short range in soft tissue is limited to only a few cell diameters. The delivery of such high energy in such a small volume, or high-linear-energy-transfer (LET), makes alpha particles especially well suited for targeting micrometastatic disease and single tumor cells such as leukemia and other blood-borne disease.

IPSCIO Record ID: 27942

License Grant
The Company announced that it had begun to develop its lung cancer-specific drug compound L-DOS47.

For this purpose, the Company entered into a worldwide exclusive license with the Licensor, through which it obtained the right to combine an antibody that specifically binds to lung adenocarcinoma cells with minimal cross reactivity to other tissues with Company's DOS47â„¢ technology.

License Property
A patent application in respect of the antibody has been filed in Canada, the United States, and as a PCT filing. L-DOS47 is still in the pre-clinical stage though the Company intends to seek approval from the FDA for a Phase I clinical study in lung adenocarcinoma patients.
Field of Use
The rights granted relate to biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the treatment and prevention of cancer based on its proprietary technologies.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.